With a top-to-bottom review of operations under way, GNC Holdings Inc. is looking for ways to shore up a stock that’s carrying half the value it had just nine months ago.
In a sparingly worded three-paragraph news release Monday, the GNC board said it may consider selling the company — or take no action at all. But, after hiring Goldman Sachs as financial adviser and a New York City law firm as legal adviser, some degree of change seems inevitable.
“We are in the early stages of a broad review and will take the time we need to thoroughly evaluate our opportunities to achieve the best result for our shareholders, business partners and associates,” Mike Archbold, president and CEO, said in an email Monday.
Among its other options, the Downtown-based company says it will look at stepping up the conversion of company-owned stores to franchisees or possibly seek a partnership or collaboration while looking at ways to optimize how the company is financed.
The trigger for the review is no mystery after last week’s dismal first quarter financial disclosure revealed a 23 percent drop in net revenue from a year ago.
While the vitamin sector as a whole has slowed, GNC separately was hurt by marketing efforts that didn’t meet expectations and an inventory management problem that forced it to discount products nearing their expiration date.
GNC shares briefly fell below $25 last week, a neighborhood they hadn’t visited since 2011 and a far cry from the 52-week high of $51.69 in early August.
The vitamin retailer has seen wild swings before.
In what must now seem ages ago, GNC launched its most recent IPO in April 2011 not long after negotiations fell through to sell the company to Bright Food in China. A year later, GNC shares were selling at nearly double the first-day price of $16.60, eventually reaching the $60 mark in November 2013.
The first half of 2014 saw a precipitous drop in GNC shares, which company officials attributed in part to the harsh winter and negative media coverage that included articles in the Annals of Internal Medicine questioning the health benefits of vitamins and supplements. One analyst also suggested the stock may have “gotten a little ahead of itself” at the $60 share price.
The 2014 drop culminated in the removal of long-time president and CEO Joe Fortunato in August. Mr. Archbold took over but his first full calendar year saw two different state attorneys general, in New York and Oregon, accusing the company of either mislabeling products or using illegal ingredients. GNC forcefully denied the allegations.
The publicity took a toll.
After 2015’s disappointing first quarter for GNC, Mr. Archbold gathered the near-600 corporate headquarter employees at the Byham Theater, Downtown, for a “vision and values” talk — part of his plan to change the culture at GNC. At the time, shares were selling for close to $45.
Last week, during the company’s quarterly financial briefing, Mr. Archbold’s message took a harder edge.
Saying the focus now is on the need to improve both short-term and long-term results, he vowed, “We are moving with a sense of urgency.”
GNC shares closed Monday up $1.66 at $26.02.
GNC stock woes
April 2011: GNC goes public, trading on New York Stock Exchange at $16.60 a share initially. As its stock price nearly doubled the first year, GNC’s IPO is considered the best performing of 2011, outdoing the likes of LinkedIn and Groupon.
August 2014: After GNC shares fall to the low-$30 range from $60 the previous November, Joe Fortunato is out as president and CEO after eight years, replaced by former Vitamin Shoppe executive Mike Archbold.
February 2015: New York attorney general sends cease-and-desist letters to GNC, Target, Walgreens and Walmart, accusing the retailers of selling herbal products with misleading ingredient labels. GNC responds that it is confident the products “are fully compliant, safe and properly labeled.”
June 2015: At all-hands meeting of GNC employees, CEO Mike Archbold acknowledges move to pull back on promotions had been too severe, leading to lower sales.
October 2015: Oregon attorney general accuses GNC of selling supplements using unapproved drugs. GNC issues denial but shares close down 14 percent at $34.50.
April 28, 2016: GNC shares fall nearly 30 percent after company releases first quarter results showing a drop in revenue caused in part by the need to steeply discount products nearing their expiration date. Four days later, GNC board members say company will conduct “a thorough evaluation of the company’s current operating plan.”
Steve Twedt: stwedt@post-gazette.com or 412-263-1963.





Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.